GlassScriptPhysician profile
Emily B Baertsch
NPI 1225669211
$2,542.20
in general payments reported to CMS, 2019-2025
12 companies · $694 in 2025
The $694 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $495 · 2023: $509 · 2024: $483 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $774.57 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $537.81 | 2022-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $315.73 | 2024-2025 | Rezdiffra |
| Janssen Biotech, INC. | $241.09 | 2021-2025 | Tremfya |
| Sirtex Medical INC | $131.83 | 2022 | |
| Ardelyx, INC. | $125.01 | 2023 | Ibsrela |
| Janssen Scientific Affairs, LLC | $124.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $103.75 | 2023 | Dupixent |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Celgene Corporation | $40.69 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $28.94 | 2024 | |
| Endogastric Solutions, INC | $17.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Baertsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.